Revefenacin in Pulmonary Disease, Chronic Obstructive: NCT07721922 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 4
Clinical phase
Not yet recruiting
Recruitment status
280
Planned enrollment
2028-09-01
Primary-completion proxy
Executive view
NCT07721922 evaluates Revefenacin in Pulmonary Disease, Chronic Obstructive. The disclosed sponsor is University of Tennessee, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Difference in Modified Borg Dyspnea Scale scores between groups, assessed over From enrollment through Day 7 (end of treatment).
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07721922 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Pulmonary Disease, Chronic Obstructive landscape. Drug & Asset MCP drug_fetch was queried for Revefenacin, while Company & Deal Intelligence MCP organization_fetch was queried for University of Tennessee.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07721922 | Revefenacin | Phase 4 / Not yet recruiting | University of Tennessee | United States | Difference in Modified Borg Dyspnea Scale scores between groups From enrollment through Day 7 (end of treatment) | 2028-09-01 |
| NCT07789899 | GSK-3862995B | Phase 1 / Recruiting | GSK Plc | United Kingdom | Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0… From pre-dose on Day 1 through Week 36 | 2027-09-07 |
| NCT07759245 | Brenipatide | Phase 2 / Not yet recruiting | Eli Lilly & Co. | United States, Argentina, Romania, Hungary, Czechia, Japan, United Kingdom, India, Canada, South Korea, Austria, China, Poland, Denmark, Mexico, France, Germany | Change from Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁) Baseline through Week 36 | 2028-05-01 |
| NCT07749001 | Mepolizumab | Phase 4 / Not yet recruiting | University of Western Ontario | Geography not reported | To measure the effect of mepolizumab (100mg) on MRI ventilation defect percent in participants with no severe exacerbat… 24-weeks and 48-weeks. | 2028-02-28 |
| NCT07747805 | Tirzepatide | Phase 2 / Not yet recruiting | The Cleveland Clinic Foundation | United States | Change in FEV1 12 months | 2028-08-15 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07721922 is a Phase 4, not yet recruiting study with 280 planned participants. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment.
The primary endpoint is “Difference in Modified Borg Dyspnea Scale scores between groups” over “From enrollment through Day 7 (end of treatment).” The retrieved endpoint description is: This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am \& pm. Scores from Group 1 and Group 2 will be averaged and compared..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 280 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Salbutamol sulfate, Ipratropium Bromide as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Pulmonary Disease, Chronic Obstructive. These records do not establish direct evidence for NCT07721922 unless the registration number matches.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a Histo…
Phase 2; n=309; Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12(Least Squares Mean): Adjusted Mean Difference = 5.3(95% CI, -57.0 to 67.6), P-Value = 0.8670; Adjusted Mean Difference = 12.0(95% CI, -56.4 to 80.3), P-Value = 0.7308; Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12(Least Squares Mean) = -20.1 milliliters (mL) (95% C… Source: https://clinicaltrials.gov/ct2/show/results/NCT02546700
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Dis…
Phase 2; n=49; Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12(Median) = 0.526 score on a scale (Full Range, -0.74 to 2.53); Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers… Source: https://clinicaltrials.gov/ct2/show/results/NCT05326412
A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Diprop…
Phase 3; n=419; Area Under the Curve (AUC) 0-30min Standardized by Time of Change From Pre-dose in Forced Expiratory Volume in One Second (FEV1) in the Morning of Day 1(Mean): Adjusted Mean Difference = 0.073(95% CI, 0.050 - 0.095), P-Value = <0.001; Area Under the Curve (AUC) 0-30min Standardized by Time of Change From Pre-dose in Forced Expiratory Volume in One Second (FEV1) in the Morning of Day 1(Mean) = 0.177 Liters (95% Confi… Source: https://clinicaltrials.gov/ct2/show/results/NCT01245569
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Revefenacin is indexed as Small molecule drug with mAChRs biology and a global stage of Approved. The asset profile lists Theravance Biopharma, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for University of Tennessee. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Revefenacin is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07721922
Protocol source: https://clinicaltrials.gov/study/NCT07721922
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Revefenacin in Pulmonary Disease, Chronic Obstructive is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Difference in Modified Borg Dyspnea Scale scores between groups and 2028-09-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
